Oxford Vaccine Trial Offers Hope Against Deadly Ebola Strain

Ed Hunt became the first person in the world to receive a promising new vaccine against a deadly form of Ebola, marking a major step forward in fighting the outbreak that has killed over 1,000 people in the Democratic Republic of Congo.

The 37-year-old UK man volunteered after watching news reports about the crisis. "After seeing news from DR Congo I thought I'd like to do my bit," Hunt told the BBC.

Scientists at the University of Oxford created the vaccine in just eight weeks using the same proven technology behind the Oxford AstraZeneca Covid vaccine that protected hundreds of millions during the pandemic. The speed came from decades of background research that let the team adapt quickly to this new threat.

The vaccine targets the Bundibugyo species of Ebola, which sparked the current outbreak. While a licensed vaccine exists for a different Ebola strain called Zaire, it doesn't protect against Bundibugyo.

Hunt is the first of 50 healthy volunteers aged 18 to 55 who will participate in the initial safety trial. Prof Teresa Lambe, who led the vaccine team, explained that researchers will check whether the vaccine triggers a strong immune response without giving anyone the actual disease.

Three more vaccines are in development for this Ebola strain, but Oxford's is the first to reach human testing. If the trials succeed, help could arrive quickly.

The Ripple Effect

The Serum Institute in India has already manufactured 600,000 doses, sitting ready to ship if the trials prove successful. This preparation means communities in DR Congo could receive protection far faster than typical vaccine development timelines allow.

Two more trials will follow soon. A small study launches in Uganda, followed by a larger efficacy trial in the Democratic Republic of Congo where the outbreak continues.

To date, more than 2,500 confirmed cases have been reported in DR Congo. The new vaccine represents hope for ending transmission and protecting healthcare workers and communities on the front lines.

Hunt's decision to roll up his sleeve represents something bigger than one volunteer. It's the first step in a carefully planned response that combines cutting-edge science, global manufacturing, and human courage to stop a deadly disease in its tracks.